The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology

被引:65
作者
Baker, EA [1 ]
Leaper, DJ [1 ]
机构
[1] Univ Hosp N Tees, Professorial Surg Unit, Stockton on Tees TS19 8P, England
关键词
matrix metalloproteinases; plasminogen activators; tissue inhibitors of metalloproteinases; plasminogen activator inhibitors; colorectal cancer;
D O I
10.1016/S0959-8049(03)00065-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to determine the expression of proteinases and inhibitors from the matrix metalloproteinase (MMP) (MMPs 1, 2, 3, 9, tissue inhibitors of metalloproteinases (TIMPs) 1, 2) and plasminogen activator ((PA) urokinase (uPA), tissue type (tPA), uPAR, plasminogen activator inhibitors (PAIs) 1, 2) systems in colorectal cancer pathology by gelatin zymography, enzyme-linked immunosorbent assays (ELISAs) and quenched fluorescent substrate hydrolysis. The levels of all studied MMPs, uPA, uPAR, TIMP-1 and PAIs were significantly greater in tumour tissues than normal tissues. However, tPA and TIMP-2 were greater in normal colon (P<0.05, Mann-Whitney) e.g. PAI-1: tumour, median 14.9 (range 0.2-80.2) ng/mg total protein; normal, 2.1 (0.1-65.0). Tumour levels of several factors, in particular MMP-1 and PAI-1, correlated with pathology, i.e. Dukes' stage, differentiation, lymphatic or vascular invasion and tumour depth. The interactions between proteinase systems in colorectal cancer are complex and the balance between active proteinases and their inhibitors is important for extracellular matrix (ECM) degradation/remodelling at each stage of the metastatic cascade. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:981 / 988
页数:8
相关论文
共 33 条
[11]  
Herszènyi L, 1999, CANCER, V86, P1135, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1135::AID-CNCR6>3.0.CO
[12]  
2-2
[13]   ELECTROPHORETIC ANALYSIS OF PLASMINOGEN ACTIVATORS IN POLYACRYLAMIDE GELS CONTAINING SODIUM DODECYL-SULFATE AND COPOLYMERIZED SUBSTRATES [J].
HEUSSEN, C ;
DOWDLE, EB .
ANALYTICAL BIOCHEMISTRY, 1980, 102 (01) :196-202
[14]   Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma [J].
Inuzuka, K ;
Ogata, Y ;
Nagase, H ;
Shirouzu, K .
JOURNAL OF SURGICAL RESEARCH, 2000, 93 (02) :211-218
[15]  
Kikuchi R, 2000, BRIT J CANCER, V83, P215
[16]   A NOVEL COUMARIN-LABELED PEPTIDE FOR SENSITIVE CONTINUOUS ASSAYS OF THE MATRIX METALLOPROTEINASES [J].
KNIGHT, CG ;
WILLENBROCK, F ;
MURPHY, G .
FEBS LETTERS, 1992, 296 (03) :263-266
[17]  
Liabakk NB, 1996, CANCER RES, V56, P190
[18]  
Mukai M, 1999, ONCOL REP, V6, P969
[19]   Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer [J].
Murray, GI ;
Duncan, ME ;
ONeil, P ;
Melvin, WT ;
Fothergill, JE .
NATURE MEDICINE, 1996, 2 (04) :461-462
[20]   SIMPLIFIED METHOD OF QUANTITATING PROTEIN USING BIURET AND PHENOL REAGENTS [J].
OHNISHI, ST ;
BARR, JK .
ANALYTICAL BIOCHEMISTRY, 1978, 86 (01) :193-200